Impaired health status in Type D patients following PCI in the drug-eluting stent era
Introduction
Despite a significant reduction in the incidence of restenosis and the need for revascularization following percutaneous coronary intervention (PCI) with drug-eluting stent implantation [1], [2], [3], subgroups of patients who have undergone a successful PCI may not benefit optimally from this invasive procedure in terms of improved health status. Health status has been identified as an important determinant of mortality [4], [5], but health status is also increasingly receiving attention as an outcome measure in its own right. Advances in the treatment of cardiovascular disease has led to a shift from hard endpoints, such as mortality and myocardial infarction (MI), to include the patient's perspective and the value of these advances to society [6]; prolonged survival is no longer the “be all and end all” but also the quality of life of the patient has become important. With this shift in outcomes, identification of subgroups at risk of impaired health status is gaining increasing importance, with knowledge of the determinants of impaired health status leading to a closing of the gap between research and clinical practice [6].
From the pre drug-eluting stent era, there is evidence to support the notion that subgroups of patients may benefit differentially from cardiac invasive procedures. In patients following PCI, vital exhaustion has been shown to predict the occurrence of new cardiac events including the need for revascularization [7]. Vital exhaustion is a mental state defined by unusual fatigue, irritability, and feelings of demoralization [7]. Prior history of depression [8] and smoking [9] also have been shown to impede the benefits of PCI on health status. Other factors associated with impaired health status include female gender [10], [11], impaired left ventricular function [12], depression [13], and the distressed (Type D) personality [14], although the majority of these studies were conducted in patients with acute coronary syndromes rather than in patients following PCI.
In a recent study of this sample, we showed that Type D personality was associated with a 5-fold increased risk of death or MI adjusting for all other factors [15]. Type D defines those individuals who tend to experience increased negative emotions and who inhibit the self-expression of these emotions in social interactions [16]. A Type D patient typically worries, has a gloomy view of life, often feels unhappy, and is a closed kind of person who prefers to keep other people at a distance. In the pre drug-eluting stent era, Type D has been associated with adverse health status at 5-years' follow-up [14], major adverse cardiac events despite appropriate treatment [16], [17], [18], and has been found to exert a large and persisting effect on symptoms of vital exhaustion and fatigue pre- and post-intervention compared with that of gender [19]. It is important to note that the impact of Type D remained substantial when adjusting for demographic and clinical risk factors, with the associated risk being 4–8 fold for adverse prognosis [16]. However, to date no study has examined whether Type D personality has a persistent adverse impact on health status. It is also not known whether the impact of Type D on health status seen in the pre drug-eluting stent era still exists in the drug-eluting stent era. Although there is clear evidence to demonstrate that personality is an important explanatory factor of individual differences in outcome [16], paradoxically the inclusion of personality factors in psychosomatic research has become unfashionable since the controversy surrounding the Type A Behavior Pattern.
The objective of the current study was two-fold: (1) To establish the stability of Type D personality as a modulator of health status at 6 and 12 months in post-PCI patients receiving a sirolimus-eluting stent (SES) or bare metal stent (BMS) implantation; (2) To investigate the clinical relevance of Type D personality as a predictor of health status at 12 months.
Section snippets
Study design and participants
The study population comprised a series of consecutive patients (n = 875; 71% response rate) treated with PCI with either SES or BMS implantation at the Erasmus Medical Center Rotterdam between October 16, 2001, and October 15, 2002, as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. The design of the RESEARCH registry [20] and the psychological sub study has been published previously [15]. In brief, the purpose of the RESEARCH registry was to
Patient characteristics
Patient characteristics stratified by Type D personality at 6 months are listed in Table 1. Type D patients were more likely to have had a recent cardiac event (p < 0.001) and to smoke compared with non-Type D patients (p < 0.01). No other significant differences were found between the two personality types on characteristics at 6 months.
Changes in health status between 6 and 12 months post-PCI
The ANOVA for repeated measures showed a general significant improvement in health status (F(1, 690) = 20.418; p < 0.001) between 6 and 12 months. Although the
Discussion
This is the first study to examine the impact of Type D personality on health status at 6 and 12 months in patients treated with PCI in the drug-eluting stent era. Although there was a general improvement in health status between 6 and 12 months, Type D patients had significantly lower scores on all health status domains as measured by the SF-36 at both time points. In addition, Type D personality was shown to be an independent predictor of impaired health status at 12 months post-PCI on all
Acknowledgements
This study was supported by the Erasmus Medical Center Rotterdam and Cordis, a Johnson & Johnson Company, Miami Lakes, USA.
References (33)
- et al.
Assessing risk for major depression in patients selected for percutaneous transluminal coronary angioplasty: is it a worthwhile venture?
Gen Hosp Psych
(2003) - et al.
Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: A Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry sub-study
J Am Coll Cardiol
(2004) - et al.
Personality as independent predictor of long term mortality in patients with coronary heart disease
Lancet
(1996) - et al.
Increased vital exhaustion among Type D patients with ischemic heart disease
J Psychosom Res
(2001) - et al.
Early outcome after sirolimus eluting stent implantation in patients with acute coronary syndromes: Insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry
J Am Coll Cardiol
(2003) - et al.
Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia
J Am Coll Cardiol
(2003) - et al.
History of depression, angina, and quality of life after acute coronary syndromes
Am Heart J
(2003) - et al.
Quality of life after balloon angioplasty or stenting for acute myocardial infarction: One-year results from the Stent-PAMI trial
J Am Coll Cardiol
(2001) - et al.
Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure
J Am Coll Cardiol
(2003) - et al.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
N Engl J Med
(2004)